ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

摘要:

For the first time in a decade, the direction of future research into combining radio- and chemotherapy is clear. For cancers with both local control problems and metastatic potential, it is generally agreed that a combined therapeutic approach provides greater benefits than either modality alone. Now, a study involving patients with small-cell lung cancer (SCLC) has provided further clarification on the best strategies for treatment. As reported at the European Cancer Conference [ECCO;Paris, France; October/November 1995], sequential therapy appears to be a better option than concomitant treatment. Researchers are now faced with the task of improving each of the components in this combination.

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

摘要:

Several pharmaceutical companies worldwide have joined in a race to develop new antifungal agents for patients with compromised immune systems. Prominent at the 35th International Conference on Antimicrobial Agents and Chemotherapy [San Francisco, US; September 1995] were presentations from Pfizer and Schering-Plough on their new azole derivatives UK-109496 and SCH-56592, which are at phase II and preclinical stages of development, respectively.

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS

ISSN:1173-8324    

出版商:ADIS    

年代:1995

数据来源: ADIS